Cardiometabolic phenotype linked to fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease.

Abstract excerpt

BACKGROUND AND AIMS: Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) often manifest a combination of cardiometabolic risk factors of varying severity. The cardiometabolic phenotypes and their associations with advanced liver fibrosis and all-cause mortality among patients with MASLD warrant further investigation. METHODS AND RESULTS: A total of 4209 and 1901 eligible participants...

Topics

Join the communities discussing this publication.

• Blood Glucose
• Cardiometabolic Risk Factors
• Cause of Death
• Fatty Liver
• Liver Cirrhosis